Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Tadeusz Robak(Medical University of Lodz), Stephen Jolles(University Hospital of Wales), Rose Snipes(UCB Pharma (United States)), Vasile Musteata, Isidro Jarque(Hospital Universitari i Politècnic La Fe), Ute Massow(UCB Pharma (Germany)), James B. Bussel(NewYork–Presbyterian Hospital), Peter Kießling(UCB Pharma (Germany)), Franz Woltering(UCB Pharma (Germany)), Juan Ke(UCB Pharma (United Kingdom)), Maciej Kaźmierczak(Silesian University of Technology), Jacek Treliński(Copernicus Memorial Hospital), Grant Langdon, Nichola Cooper(Imperial College London)
Cited by 109
Related Papers
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907